Anticancer effects of vitamin K combined with transarterial chemoembolization in hepatocellular carcinoma, a randomized controlled trial
Mené sur 101 patients atteints d'un carcinome hépatocellulaire non résécable, cet essai randomisé évalue l'efficacité, du point de vue du taux de réponse objective et de la survie sans progression, d'un ajout de vitamine K à une chimioembolisation transartérielle hépatique
Background: We have previously reported that vitamin K dosing augments the anticancer effects of sorafenib by suppressing levels of des-
γ-carboxy prothrombin, a known tumor growth and angiogenesis factor produced in HCC under sorafenib-induced ischemia. Herein, we aimed to establish whether vitamin K dosing could afford a similar anticancer effect when combined with transarterial chemoembolization (TACE).
Methods
:
We performed a randomized controlled trial, assigning patients with unresectable HCC (1:1) to TACE
+ vitamin K or TACE alone groups. Co-primary endpoints were objective response rate and PFS; the secondary endpoint was safety.
Results: The TACE + vitamin K group (n = 50) exhibited a significantly higher objective response rate than the TACE alone group (n = 51) (96.0% vs. 82.4%, p = 0.028). The PFS was significantly longer in the TACE + vitamin K group than that in the TACE alone group (median time: 262 days [95% confidence interval (CI), 35.8–488.2 days] vs. 146 days [95% CI, 111.6–180.4 days]; p = 0.013, hazard ratio: 0.55 [95% CI, 0.34–0.89]). There were no significant differences in the incidence of adverse events between groups.
Conclusions: Compared with TACE alone, vitamin K dosing combined with TACE improved anticancer outcomes.
British Journal of Cancer , article en libre accès 2025